Globus Medical (GMED) Announces Third Quarter 2025 Earnings Results

Globus Medical, Inc. (GMED) today announced its financial results for the most recent quarter, showcasing a strong performance that exceeded expectations. The company reported earnings per share of $0.88, beating the consensus estimate of $0.78 by a notable margin. Additionally, Globus Medical achieved quarterly revenue of $769.0 million, surpassing the revenue estimate of $734.7 million by approximately $34.4 million.

Key Highlights:

• Globus Medical reported third-quarter 2025 net sales of $769.0 million, a 22.9% increase year-over-year.
• U.S. net sales increased by 24.6%, while international sales rose by 16.5%.
• GAAP net income for the quarter was $119.0 million, a 129.5% increase compared to the previous year.
• Non-GAAP diluted earnings per share (EPS) was $1.18, up 42.6% from the prior year.
• The company increased its full-year 2025 revenue guidance to $2.86 to $2.90 billion and non-GAAP EPS guidance to $3.75 to $3.85.
• The Nevro acquisition is expected to be accretive to earnings in 2025.

In the third quarter of 2025, Globus Medical demonstrated strong financial performance, with a notable 22.9% increase in worldwide net sales, reaching $769.0 million. The growth was driven by a 10% increase in the U.S. Spine business and the successful integration of the recently acquired Nevro business, which contributed $99.3 million to sales. Keith Pfeil, President and CEO, expressed satisfaction with the company’s progress, stating, “Q3 revenue rose 23%, driven by broad-based demand across our products and geographies.” The company also reported significant improvements in adjusted gross margins and operating expenses, reflecting operational efficiencies from the NuVasive merger and Nevro acquisition.

Looking ahead, Globus Medical is optimistic about maintaining its growth trajectory. The company has raised its revenue and EPS guidance for the full year, indicating confidence in its strategic direction and operational execution. CFO Kyle Kline highlighted the company’s ability to balance growth with operational efficiency, noting a record non-GAAP free cash flow of $213.9 million for the quarter. He stated, “We’ve executed share repurchases of $40 million this past quarter, bringing our total repurchases to $255.5 million through the first nine months of 2025,” underscoring the company’s commitment to delivering long-term value to shareholders.

Globus Medical, Inc. (GMED) has experienced a rollercoaster ride in its stock price, with a notable 16.81% increase over the past three months, signaling a potential rebound after a challenging year that saw a 25.39% decline. Despite the recent uptick, the stock remains under pressure, having dropped 12.38% over the last six months. On the fundamental side, GMED showcases impressive growth metrics, with a two-year compound annual growth rate (CAGR) in revenue of 54.74% and free cash flow soaring at 107.74%. This robust financial performance is further underscored by a solid net profit margin of 13.04% and a return on invested capital of 8.39%. The company’s price-to-earnings ratio of 23.57 suggests that investors are willing to pay a premium for its growth potential, especially given the strong earnings per share CAGR of 13.69%. As GMED navigates the market’s ups and downs, its impressive fundamentals may provide a cushion against volatility, making it a stock to watch in the coming months.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.